Takeda Pharmaceutical Co. $TAK Shares Sold by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership cut its holdings in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 13.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,218,690 shares of the company’s stock after selling 181,766 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in Takeda Pharmaceutical were worth $18,841,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Takeda Pharmaceutical during the 1st quarter valued at $51,049,000. Goldman Sachs Group Inc. raised its position in shares of Takeda Pharmaceutical by 15.0% during the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock worth $79,120,000 after purchasing an additional 692,404 shares during the period. Brandes Investment Partners LP raised its position in shares of Takeda Pharmaceutical by 5.9% during the second quarter. Brandes Investment Partners LP now owns 3,712,278 shares of the company’s stock worth $57,392,000 after purchasing an additional 208,136 shares during the period. Graham Capital Management L.P. purchased a new stake in shares of Takeda Pharmaceutical during the first quarter valued at $2,361,000. Finally, Carrera Capital Advisors acquired a new position in shares of Takeda Pharmaceutical in the 2nd quarter valued at $2,153,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the company. Weiss Ratings restated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a report on Monday, December 1st. Zacks Research lowered shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Thursday, August 21st. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Takeda Pharmaceutical currently has an average rating of “Hold”.

Takeda Pharmaceutical Trading Down 0.7%

Takeda Pharmaceutical stock opened at $14.18 on Monday. Takeda Pharmaceutical Co. has a 12 month low of $12.80 and a 12 month high of $15.69. The company has a quick ratio of 0.76, a current ratio of 1.37 and a debt-to-equity ratio of 0.61. The stock has a market cap of $45.10 billion, a P/E ratio of 177.19 and a beta of 0.03. The company’s fifty day simple moving average is $14.11 and its 200-day simple moving average is $14.62.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Thursday, October 30th. The company reported $0.44 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.44. Takeda Pharmaceutical had a return on equity of 10.32% and a net margin of 0.86%.The firm had revenue of $7.30 billion during the quarter, compared to analysts’ expectations of $8.01 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. As a group, sell-side analysts forecast that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.